A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant89Zr-immuno-PET agents-Reference-Cited by-同舟云学术

A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant89Zr-immuno-PET agents

Published:2018 Issue:37 Volume:47 Page:13214-13221
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Bhatt Nikunj B.¹²³⁴,Pandya Darpan N.¹²³⁴^ORCID,Rideout-Danner Stephanie⁵²³⁴,Gage Howard D.⁵²³⁴^ORCID,Marini Frank C.¹²³⁴⁶,Wadas Thaddeus J.¹²³⁴^ORCID

Affiliation:

1. Department of Cancer Biology

2. Wake Forest School of Medicine

3. Winston-Salem

4. USA

5. Department of Radiology

6. Wake Forest Institute of Regenerative Medicine

Abstract

Zirconium-89 is currently being used in numerous clinical trials involving monoclonal antibodies and positron emission tomography. A comprehensively revised protocol for the production, quality control and long-term storage of⁸⁹Zr-immuno-PET radiopharmaceuticals.

Funder

North Carolina Biotechnology Center

National Center for Advancing Translational Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/DT/C8DT01841C

Reference79 articles.

1. Recent Advances in Zirconium-89 Chelator Development

2. ⁸⁹Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals